O2-01-05

Xue Zhang,Feng Li,Ayelen Bulloj,Yun-wu Zhang,Gang Tong,Zhuohua Zhang,Francesca-Fang Liao,Huaxi Xu

DOI: https://doi.org/10.1016/j.jalz.2006.05.106

2007-01-01

Abstract:Neurofibrillary tangles (NFTs), consisting of aggregates of abnormally hyperphosphorylated tau, are indicated in the pathogenesis of several neurodegenerative diseases including Alzheimer's disease (AD). Although hyperphosphorylation of tau is thought to cause aggregation and dissociation of tau from microtubules, the molecular mechanisms underlying the regulation of tau phosphorylation are largely unknown. While the PI3K/Akt pathway has increasingly been shown to regulate multiple cellular events pertinent to AD pathogenesis, including β–amyloid metabolism and tau phosphorylation via GSK–3, potential functions of tumor suppressor PTEN in AD pathogenesis have not been explored. In our study, we explored the molecular mechanisms for regulation of tau phosphorylation by asking the question that if PTEN, a tumor suppressor in PI3K/Akt signaling pathway, can affect tau phosphorylation at Akt and GSK–3 phosphorylation sites and the consequential effects on tau aggregation and binding to microtubules. We examined the effects of PTEN on tau phosphorylation, its microtubule association and formation of aggregates. We cotransfected COS–7 cells with human tau and human wild–type or phosphatase activity null mutant PTEN. We evaluated PTEN's effects on tau phosphorylation by using phospho–tau specific antibodies. To assess PTEN's effects on tau aggregation and binding to microtubules, we performed filter–retardation assay to detect and compare tau aggregates in cultured cells in the presence of wild–type or mutant PTEN. In addition, we fractioned the cotransfected cells to detect and compare the cytosolic, microtubule–bound, membrane–bound and insoluble aggregated tau between cells expressing wild–type and the mutant PTEN. Moreover, we infected rat cortical primary neurons with Sindbis viruses expressing wild–type or the mutant PTEN to monitor neuronal growth. At last, we performed immunohistology to compare phospho–tau and PTEN levels between AD patient and non–AD brains. 1. PTEN affects tau phosphorylation at Akt and GSK–3 phosphorylation sites. 2. PTEN affects tau aggregation and binding to microtubules. 3. PTEN's effects on tau phosphorylation are partially through PIP3/Akt signaling pathway.